Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Alzamend Neuro Inc (ALZN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ALZN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -39.81% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.57M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 690287 | Beta -0.01 | 52 Weeks Range 0.64 - 9.30 | Updated Date 04/2/2025 |
52 Weeks Range 0.64 - 9.30 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -134.51 |
Earnings Date
Report Date 2025-03-17 | When - | Estimate -0.355 | Actual -0.19 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -106.08% | Return on Equity (TTM) -1092.96% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6489845 | Price to Sales(TTM) - |
Enterprise Value 6489845 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.13 | Shares Outstanding 6597510 | Shares Floating 6443125 |
Shares Outstanding 6597510 | Shares Floating 6443125 | ||
Percent Insiders 3.52 | Percent Institutions 1.72 |
Analyst Ratings
Rating 5 | Target Price 32 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Alzamend Neuro Inc
Company Overview
History and Background
Alzamend Neuro, Inc., was incorporated on February 9, 2015. The company is focused on developing novel products for the treatment of Alzheimer's disease, bipolar disorder, depression, and post-traumatic stress disorder (PTSD).
Core Business Areas
- Alzheimer's Disease Drug Development: Focuses on developing new therapies for Alzheimer's, including AL001, a lithium-delivery system, and ALZN002, an immunotherapy product.
- Mental Health Drug Development: Exploration of treatments for bipolar disorder, depression, and PTSD.
Leadership and Structure
Stephan Jackman is the Chief Executive Officer. The company has a board of directors and a management team overseeing its research and development activities.
Top Products and Market Share
Key Offerings
- AL001: A lithium-delivery system designed to deliver a stabilized dosage of lithium to treat Alzheimer's disease, bipolar disorder, depression and PTSD. Currently in development; no market share or revenue data available. Competitors: Acadia Pharmaceuticals, Biogen, Eli Lilly.
- ALZN002: A patented cell-based therapeutic vaccine to treat Alzheimeru2019s. Currently in pre-clinical trials; no market share or revenue data available. Competitors: Biogen, Roche, Eisai.
Market Dynamics
Industry Overview
The Alzheimer's disease treatment market is large and growing due to an aging population. Significant unmet needs exist for effective therapies.
Positioning
Alzamend Neuro is a small biotechnology company focused on developing novel therapies. Its competitive advantage lies in its unique drug delivery system for lithium and vaccine platform for Alzheimer's.
Total Addressable Market (TAM)
The global Alzheimer's disease therapeutics market is projected to reach billions of dollars. Alzamend is a small player with potential upside if its products are approved.
Upturn SWOT Analysis
Strengths
- Novel drug delivery system (AL001)
- Patented cell-based therapeutic vaccine (ALZN002)
- Experienced management team in drug development
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Early stage of development (high risk)
- Dependence on successful clinical trials
- No currently marketed products
Opportunities
- Partnerships with larger pharmaceutical companies
- Grant funding opportunities
- Fast track approval pathways for Alzheimer's drugs
- Positive clinical trial results
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- ABBV
Competitive Landscape
Alzamend Neuro faces intense competition from larger, more established pharmaceutical companies. Its success depends on its ability to differentiate its products and secure funding.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth due to being in early stages.
Future Projections: Future growth depends on successful clinical trials and regulatory approvals. Analyst projections are speculative.
Recent Initiatives: Focus on advancing AL001 and ALZN002 through clinical trials.
Summary
Alzamend Neuro is a high-risk, high-reward biotechnology company focusing on Alzheimer's disease and mental health. Its novel drug delivery and vaccine platforms offer promise, but clinical trial success and funding are critical. The company faces strong competition from established players and regulatory hurdles. Investing in Alzamend Neuro is highly speculative and not suitable for risk-averse investors.
Similar Companies
ACAD
ACADIA Pharmaceuticals Inc
ACAD
ACADIA Pharmaceuticals Inc
BIIB
Biogen Inc
BIIB
Biogen Inc
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on available information and may be subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alzamend Neuro Inc
Exchange NASDAQ | Headquaters Atlanta, GA, United States | ||
IPO Launch date 2021-06-15 | CEO & Director Mr. Stephan Jackman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.alzamend.com |
Full time employees 4 | Website https://www.alzamend.com | ||
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.